Wonisch, W.; Tatzber, F.; Lindschinger, M.; Falk, A.; Resch, U.; Mörkl, S.; Zarkovic, N.; Cvirn, G.
Overview of Clinical Relevance of Antibodies Against Oxidized Low-Density Lipoprotein (oLAb) Within Three Decades by ELISA Technology. Antioxidants 2024, 13, 1560.
https://doi.org/10.3390/antiox13121560
AMA Style
Wonisch W, Tatzber F, Lindschinger M, Falk A, Resch U, Mörkl S, Zarkovic N, Cvirn G.
Overview of Clinical Relevance of Antibodies Against Oxidized Low-Density Lipoprotein (oLAb) Within Three Decades by ELISA Technology. Antioxidants. 2024; 13(12):1560.
https://doi.org/10.3390/antiox13121560
Chicago/Turabian Style
Wonisch, Willibald, Franz Tatzber, Meinrad Lindschinger, Andreas Falk, Ulrike Resch, Sabrina Mörkl, Neven Zarkovic, and Gerhard Cvirn.
2024. "Overview of Clinical Relevance of Antibodies Against Oxidized Low-Density Lipoprotein (oLAb) Within Three Decades by ELISA Technology" Antioxidants 13, no. 12: 1560.
https://doi.org/10.3390/antiox13121560
APA Style
Wonisch, W., Tatzber, F., Lindschinger, M., Falk, A., Resch, U., Mörkl, S., Zarkovic, N., & Cvirn, G.
(2024). Overview of Clinical Relevance of Antibodies Against Oxidized Low-Density Lipoprotein (oLAb) Within Three Decades by ELISA Technology. Antioxidants, 13(12), 1560.
https://doi.org/10.3390/antiox13121560
